Circadian disturbances and nocturnal problems such as sleeplessness are common among Alzheimer's disease (AD) patients and are major contributing factors for institutionalization (Pollak and Perlick, 1991; Weldemichael and Grossberg, 2010) . Evidence suggests that sleep is disrupted in AD (Prinz et al., 1982) , and sleep disorders may increase the risk of AD (Osorio et al., 2011 (Osorio et al., , 2015 . Recent studies in humans and animal models suggest that a bidirectional relationship exists between sleep/wake behavior and amyloid-b (Ab), a small peptide that is associated with plaque formation and is found in AD patients (Kang et al., 2009; Roh et al., 2012; Ju et al., 2013; Rothman et al., 2013; Spira et al., 2013; Liguori et al., 2014; Mander et al., 2015; Sprecher et al., 2015) . Ab is produced following sequential cleavage of the amyloid precursor protein by b-and g-secretases (Haass and Selkoe, 2007 ) and begins to aggregate in the human brain years before clinical symptoms, neuronal damage, and synaptic loss in AD (Holtzman et al., 2011a; Sperling et al., 2011) . Ab aggregation forms the hallmark of insoluble plaques observed in AD pathology, and it is known that clinically asymptomatic people already have reduced steady-state functional connectivity in brain areas containing amyloid deposits (Sperling et al., 2009; Sheline et al., 2010) . This suggests that other biomarkers of preclinical AD associated with Ab deposition may exist, and the identification of such factors is essential for developing SIGNIFICANCE Sleep problems are common among Alzheimer's disease (AD) patients and are a major contributing factor for institutionalization. Clinical studies have suggested a bidirectional relationship between sleep and amyloid-b (Ab), a small peptide associated with plaque formation in AD. Recent biomarker studies show associations between AD and fatty acid binding proteins (Fabps) . Fabps are reduced in brains of AD patients but elevated in the cerebrospinal fluid and sera compared with healthy individuals. Knowledge of the relationships among Ab, Fabp expression, and underlying sleep disturbance would aid in understanding AD pathogenesis and may guide therapeutic strategies to delay AD disease progression.
treatments to slow or prevent AD pathogenesis (Holtzman et al., 2011b) .
Levels of Ab in cerebrospinal fluid (CSF) cycle based on time of day in humans, with a progressive decline in circadian amplitude occurring with age and amyloid deposition . Diurnal cycling of Ab has also been shown to be correlated negatively with Ab aggregation and increased wakefulness (Roh et al., 2012) . Ab concentrations are elevated following periods of chronic sleep restriction in AD mouse models (Kang et al., 2009; Rothman et al., 2013) , supporting a positive feedback loop hypothesis among Ab levels, clearance, aggregation, and the sleep/wake cycle (Gerstner et al., 2012a; Ju et al., 2013; Lim et al., 2014) . Given that Ab levels are higher during periods of wakefulness (Kang et al., 2009) and that the peak in amplitude of cycling Ab levels in human CSF precedes the peak in total sleep time by 6 hr , we test the hypothesis that neural expression of Ab increases wakefulness and disrupts consolidated sleep. Sleep disturbance is thought to occur at ages prior to the onset of cognitive deficits in AD and therefore could represent a preclinical marker (Ju et al., 2014) . Because of the link between sleep disturbance and Ab levels, we also examine whether any Ab-induced sleep disruption exists at ages prior to the onset of traditionally established AD phenotypic markers.
The fruit fly Drosophila melanogaster is an excellent animal model system for testing these questions for three reasons. First, the fly AD model recapitulates most of the clinically relevant hallmark traits of the disease, including the formation of amyloid deposits, progressive memory loss, neurodegeneration, and premature death (Iijima et al., 2004; Iijima-Ando and Iijima, 2010) . Second, Drosophila is an established model for studying sleep/wake behavior, and, unlike wild-type mice, which have comparatively more fragmented sleep and are nocturnal, Drosophila has a very consolidated period of sleep during the dark phase of the light-dark cycle (Ho and Sehgal, 2005; Cirelli and Bushey, 2008; Zimmerman et al., 2008) . This becomes more fragmented with aging Bushey et al., 2010; Koudounas et al., 2012) . Third, the fly model offers the opportunity to evaluate rapidly specific genetic targets that could inform the therapeutic potential for treatments that delay or prevent neurodegenerative disease (Bilen and Bonini, 2005; Lu and Vogel, 2009 ).
This current study shows that flies that express human Ab have significant sleep fragmentation at 2 or 3 days posteclosion, an age prodromal to memory deficits previously reported in adult flies (Iijima et al., 2004) . AD flies that contain either the fly fatty acid binding proteins (Fabp) or the murine Fabp7 transgene rescue the Abinduced disruption in consolidated sleep. These findings suggest that 1) Ab neuronal expression affects sleep quality, 2) Ab-induced sleep fragmentation may be an early marker in the course of human AD, and 3) therapeutic approaches targeting Fabp may have clinical implications for reducing sleep-associated disturbances observed in AD.
MATERIALS AND METHODS

Drosophila Genetics and Stocks
Male flies (D. melanogaster) carrying a human Ab42 transgene expressed in the presence of neuronal promoter elav (C155-GAL4; Finelli et al., 2004; Iijima et al., 2004) were examined for changes in sleep compared with flies overexpressing either dFabp or mFabp7 (Gerstner et al., 2011a,b) with a video monitoring assay (Zimmerman et al., 2008) . The parental genotypes of flies used in this study were elav c155 -GAL4/Y (elav-GAL4; obtained from J. Williams), GeneSwitch (GS)-elav-GAL4 (GS-elav-GAL4; Bloomington), UAS-Ab42 (obtained from M. Konsolaki), hs-dFabp (101-4), hs-mFabp7 (103-5), and the isogenic w (isoCJ1) background strain (Gerstner et al., 2011b) . Fly genotypes were all back-crossed into the w(isoCJ1) background for a minimum of six generations and are summarized in Table I , with descriptions of each genotype and abbreviations. For the GeneSwitch experiments (Vanderheyden et al., 2013) , food was prepared by vortexing RU486 (mifepristone) with melted food and allowing the mixture to solidify. Briefly, 500 lM RU486 dissolved in 80% ethanol was prepared in 1% agar and 5% sucrose minimal media. Flies were first recorded in tubes containing only 1% agar and 5% sucrose minimal media and after 2 days were switched to minimal media containing drug or vehicle and were replaced under the camera for the duration of the recording. Heat-shock treatment consisted of increasing the ambient room temperature to 298C for 3 days following baseline recording.
Sleep Behavior
Flies were collected following eclosion and placed on standard cornmeal agar media. Two or three days after eclosion, flies were transferred individually under CO 2 anesthesia into tubes 6 cm long containing food at one end and a yarn plug at the other. Behavioral recordings of fly sleep were collected under a 12-hr white light:12 hr-infrared light (wavelength 950 nm) cycle at 258C in Precision Instruments 818 incubators equipped with two fluorescent bulbs and two infrared lights mounted horizontally beside cameras (Zimmerman et al., 2008) . Cameras took an image every 5 sec, and pixel subtraction was used for Matlab CSCN analysis (software obtained from Dr. Pack, allan.pack@uphs.upenn.edu) to track movement of flies. Sleep is defined as 5 min or more of continuous inactivity, the minimum amount of time to qualify as a single sleep bout. The assessment of activity/inactivity is explained more fully below. Zeitgeber time (ZT) 0 is defined as the time of lights on, and ZT12 is defined as the time of lights off. Daytime sleep measures were from lights on to lights off (ZT0-ZT12), nighttime measures were from lights off to lights on (ZT12-ZT24). Average sleep-bout duration is defined as the mean of all sleep bouts for the given period for the group. Average maximal sleep bout duration is defined as the mean of the longest sleep bout of all flies within a group. Bout counts are defined as the mean number of transitions between sleep and wake states for the group. Latency is defined as the amount of time to first sleep episode following lights off (ZT12).
Consolidation Index
Consolidation index (CI) is a measure of consolidation of sleep for a group. Greater CI values reflect less interrupted sleep (i.e., less sleep fragmentation), whereas lower CI values indicate more sleep fragmentation. CI was calculated by summing the square of all sleep-bout lengths (in minutes) and dividing by the total amount of sleep (Pitman et al., 2006) .
Locomotor Activity
The digital image analysis method previously described is based on frame subtraction and was used to determine a quiescent fly from a moving fly (Zimmerman et al., 2008) as well as to calculate locomotor activity. The amount of movement of a fly was calculated by summing the number of pixels changed between consecutive subtracted images at the same sampling rate used to determine sleep (5 sec). Briefly, corresponding pixels from two temporally adjacent images were subtracted and a resulting difference image was generated. Each pixel in the difference image has the value GS(XiYj) 5 ([GS2(XiYj) 2 GS1(XiYj)]/2) 1 127, where GS(XiYj) is the difference image gray-scale value centered around a value of 127 at pixels X position i and Y position j, and GS2 and GS1 are the gray-scale values at that same pixel for the second and first video frames, respectively, in a pair of temporally adjacent frames. The images were digitized with eight bits per pixel; therefore, the range in gray-scale values for a single pixel was from 0 to 255. Areas of interest corresponding to each monitor tube, i.e., each fly, were analyzed separately. Gray pixels, ones in which motion did not occur, have values close to 127. They are not exactly 127 because of noise in image acquisition. Because the degree of noise varied between incubators and cameras, for every experiment the degree of this noise was determined by analyzing a portion of the image that was outside the monitoring tubes and, therefore, contained no movement. Movement per minute awake was defined by summing the number of pixels changed between images accounting for this inherent noise and dividing by the amount of time (minutes) spent in wakefulness over each 1-hr bin.
Reverse-Transcription Quantitative Polymerase Chain Reaction
RNA transcript levels were determined with reversetranscription quantitative polymerase chain reaction (RTqPCR). For qPCR experiments, 50 fly heads were collected at ZT6 for each of six biological replicates. RNA was isolated with Trizol reagent (Life Technologies, Grand Island, NY) according to the manufacturer's protocol, with the addition of an overnight incubation in isopropanol at -208C before a 30-min centrifugation at 13,000g at 48C to precipitate the RNA. RNA pellets were resuspended in nuclease-free water and subjected to an RQ1 RNase-Free DNase (Promega, Madison, WI) treatment according the manufacturer's protocol, followed by a second RNA purification as before. RNA was quantified with an ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Complementary DNA was generated with the High Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) and 4 lg of total RNA. The reaction volume was brought to 20 ll total volume with PCR-grade water, and the cDNA synthesis was completed with the PTC-100 programmable thermal controller (MJ Research, Quebec, Canada) according to the kit's instructions. Quantitative PCR was carried out with PowerSYBR Green PCR master mix (Applied Biosystems) and 10 ng cDNA per reaction, with technical duplicates of each sample. All reactions were performed with the 7900HT Fast Real-Time PCR System (Applied Biosystems) and analyzed in the 7900HT software Science Detection System 2.4. The primers used were dFabp-AB forward primer ATCATCACCCTGGATGGCAA, reverse primer ATGGTGAGGGTGGTGATCAG; mFabp7 forward primer CCAGCTGGGAGAAGAGTTTG, reverse primer TT TCTTTGCCATCCCACTTC; hAB42 forward primer GCA GAATTCCGACATGACTCA, reverse primer TGCACCTT TGTTTGAACCCA; dGapdh2 forward primer TTTCTCAG CCATCACAGTCG, reverse primer CCGATGCGACCA AATCCATT; actin forward primer ACACACCCATTGCAG ACAAA, reverse primer TTCTGAAGGAGCGGAAGTGT; and RPL32 forward primer GCTAAGCTGTCGCACAAA TGG, reverse primer GGTGGGCAGCATGTGG. The results Ab42; GS-elav 2 w; UAS-Ab42; 1 UAS-Ab42 (control) UAS-Ab42/1 3 w ;1; GeneSwitch-elav-GAL4 GeneSwtich-elav-GAL4 Driver (control) GS-elav/1 4 w (isoCJI); 1; 1 wild type isogenic background strain (also known as 2202U; control) w (isoCJI) 5 w. elav-GAL4; 1; 1 elav-GAL4 Driver (control) elav/Y 6 w, elav-GAL4; UAS-Ab42; 1 elav-GAL4 WITH UAS-Ab42 (for constitutive expression of Ab42 specifically in neurons)
Ab42/1 7 w; UAS-Ab42; hs-dFabp UAS-Ab42 with hs-dFabp (control) UAS-Ab42/1; dFabp/1 8 w, elav-GAL4; 1; hs-dFabp elav-GAL4 with hs-dFabp (control) dFabp/1 9 w, elav-GAL4; UAS-Ab42; hs-dFabp elav-GAL4 with UAS-Ab42 and hs-dFabp (for constitutive expression of Ab42 specifically in neurons, with dFabp overexpression)
Ab42/1; dFabp/1 10 w, elav-GAL4; UAS-Ab42; hs-mFabp7 elav-GAL4 with UAS-Ab42 and hs-mFabp7 (for constitutive expression of Ab42 specifically in neurons, with mFabp7 overexpression)
Ab42/1; mFabp7/1
were normalized against the geometric mean of the mRNA levels of the three housekeeping genes dGapdh2, actin, and RPL32 to determine the DCt (cycle threshold) values. For GeneSwitch studies, 50 fly heads were collected at ZT6 for each of six biological replicates with either 3 or 4 days of RU486 or vehicle treatment (as described above), and RNA was prepared and quantified as above.
Western Blotting
For each genotype, 50 fly heads were homogenized in Tris-HCl buffer with protease inhibitor cocktail (P2714; Sigma, St. Louis, MO) for 45 sec and centrifuged at 14,000 rpm for 1 min. Lysate samples were separated on 12% Tris-HCl 0.75-mm gels and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA). The membranes were blocked with 5% nonfat dry milk (Nestl e, Vevey, Switzerland) and blotted with antidFabp antibody (1:1,000), antiactin antibody (1:1,000; Cell Signaling Technology, Danvers, MA), and anti-rabbit secondary antibody IR 680 (1:5,000, Li-Cor Biosciences, Lincoln, NE) according to previously published methods (Gerstner et al., 2011a,b) . Each time point had three biological replicates and consisted of 50 fly heads pooled per time point (n 5 50 3 3 biological replicates).
Antibody Characterization
See Table II for a list of all antibodies used. The b-actin antiserum recognized only the expected monomeric (45 kD) band on Western blot of Drosophila head lysate. The dFabp antiserum recognized a single band of 14.5-kD molecular weight on Western blot of Drosophila head lysate (Gerstner et al., 2011b) .
Statistical Analysis
Statistical significance was determined by a two-tailed Student's t-test, and whether equal variance is assumed for each test is indicated. Unless otherwise indicated, we used one-way or two-way ANOVA (SigmaPlot 11) and post hoc tests (for example, Holm-Sidak to test multiple comparisons). P < 0.05 was considered significant. Flies were excluded from sleep analysis if they died during the course of the experiment, and, in the figures, when multiple days are present, sample sizes (n) are consistent throughout and are indicated in the legends.
RESULTS
Short-Term Neuronal Human Ab Expression Induces Wakefulness in Drosophila
To test the hypothesis that neuronal Ab expression increases wakefulness and disrupts consolidated sleep, we employed the GS-GAL4 system of Drosophila, which allows for the spatial and temporal control of transgene expression (Osterwalder et al., 2001; Roman et al., 2001; Nicholson et al., 2008) . In the presence of the steroid RU486, the upstream activating sequence (UAS) effector line UAS-Ab42 (Iijima et al., 2004) conditionally expresses the human Ab42 via the panneural driver GSelav-GAL4 (Osterwalder et al., 2001 ). Previous studies with a similar model have shown that the GS-elav-GAL4 system can induce UAS-driven arctic Ab42 mRNA levels with 2 days of exposure to RU486 (Rogers et al., 2012) and that the GS-inducible drug does not have any effect on sleep (Vanderheyden et al., 2013) . Short-term neuronal expression (3 days) of Ab42 in adult w;UASAb42;GS-elav-GAL4(Ab42;GS-elav) flies yielded a significant increase in Ab42 transcript levels but not in w;UASAb42;1(UAS-Ab42/1) or w;1;GS-elav-GAL4 (GSelav/1) control flies (Fig. 1A) . We also observed a decrease in sleep specific to the daytime in Ab42;GS-elav flies following short-term expression of Ab42 ( Fig. 2A) . The average daytime sleep-bout length and the average maximum daytime sleep-bout length were both reduced after short-term neural Ab42 activation (Fig. 2B,C) . The number of daytime bouts was also significantly increased after Ab42 neural expression (Fig. 2D) , whereas the CI (a measure of consolidated sleep) was concomitantly reduced (Fig. 2E) . No difference was observed in nighttime consolidation (Fig. 2F) . The reduction in daytime sleep was not due to increased activity (defined as pixels moved) because daytime movements were unchanged between RU486-treated and untreated control flies (Fig. 2G) . However, Ab induced a reduction in nighttime activity (Fig. 2H) . Total nighttime sleep, average night bout length, average maximum night bout length, average number of night bouts, and latency to sleep following lights off were not significantly affected between RU486-treated and untreated flies (data not shown). Analysis of individual days of RU486 treatment revealed a progressive decrease in average daytime sleep-bout length and average maximum daytime bout length (Fig. 3A,B) over the 3 days of observation. This progressive loss in 1:1000 consolidated daytime sleep was not associated with any changes in daytime activity (Figs. 2G, 3C ). However, Ab-induced nighttime activity was reduced on days 1-3 (Fig. 3D ). These data indicate that Ab expression alone can modulate daytime sleep and that these effects are not explained by changes in movement.
Constitutive Neuronal Expression of Human Ab Disrupts Both Daytime and Nighttime Sleep in Drosophila
Because we had observed that short-term neuronal expression of Ab can modulate sleep and that sleep disturbance may occur at ages prior to cognitive impairments in AD, we next characterized the effect of constitutive Ab expression on sleep in flies. We used a wellestablished genetic model that had been previously determined to possess the negative effects of Ab-induction, such as reduced cognitive performance, climbing ability, and survival as well as neurodegeneration (Iijima et al., 2004) . We specifically determined whether Ab-induced sleep disruption might exist at ages prior to the onset of traditionally established AD phenotypic markers. To do this, we examined sleep in 2-or 3-day-old male w,elav-GAL4;UAS-Ab42;1(Ab42/1) flies, which express UAS-Ab42 under control of the constitutive panneural driver elav-GAL4, and compared them with controls. Previous work has established that learning impairments not yet observed in 2-or 3-day-old Ab42/1 flies occur later, first appearing in males (but not yet in females) by 6 or 7 days of age, with progressive loss in both males and females by 14 or 15 days of age (Iijima et al., 2004) . Compared with 2-or 3-day-old male controls, sleep reduction was observed in age-matched Ab42/1 male flies (Fig.  4A-C,G) . This Ab-induced sleep loss in Ab42/1 flies was accompanied by a reduction in daytime maximal sleep-bout length ( Fig. 4E ) with a decrease in daytime bout number (Fig. 4F) . The average day and night sleepbout length was not affected in Ab42/1 flies compared with w,elav-GAL4;1;1(elav/Y) controls (Fig. 4D,H) . Similarly, the average maximal night sleep bout and night bout counts were not affected in Ab42/1 flies compared with w,elav-GAL4;1; 1(elav/Y) controls (Fig. 4I,J) . Control UAS-Ab42/1 flies that carry UAS-Ab42 in the absence of the driver line had more sleep time (24 hr) and more total nighttime sleep, with no differences in night bout number, night bout length, maximum night bout length, or CI compared with w(isoCJ1);1;1(w[isoCJ1]) isogenic background strain controls (Fig. 5A-F) . These data indicate that constitutive neuronal Ab expression decreases total sleep and increases sleep fragmentation and that these changes in sleep likely precede other phenotypic markers of AD, including cognitive impairments.
Constitutive Neuronal Ab Expression Effects on dFabp Protein and dFabp mRNA Levels
To determine whether Ab can influence the expression of Fabp, we measured dFabp mRNA levels with RT-qPCR in Ab42 transgenic and control flies. First, we evaluated dFabp expression in Ab42;GS-elav flies with and without RU486. We did not observe any changes in dFabp mRNA in Ab42;GS-elav flies compared with control flies (Fig. 1B) . Second, we measured levels of dFabp mRNA in Ab42/1 flies and compared them with elav/Y and UAS-Ab42/1 controls, and, again, we did not see differences (Fig. 6A) . To determine whether Ab42 affects dFabp at the protein level, we next measured dFabp at four time points across the light-dark cycle in 2-or 3-day-old male Ab42/1 flies compared with controls by Western blotting. Flies that express Ab42 appeared to have a disruption of dFabp protein levels in the light-todark transition compared with controls (Fig. 7A) . We then compared dFabp expression in Ab42/1 flies compared with elav/Y controls (Fig. 7B) and found a trend for reduction of dFabp in Ab42/1 flies (P 5 0.054, twoway ANOVA, factors genotype and time). These data Fig. 1 . RU486 induces Ab42 and does not alter dFabp mRNA expression in w;UAS-Ab42;GS-elav-GAL4 flies. A: Induction of Ab42 mRNA in w;UAS-Ab42;GS-elav-GAL4 (Ab42;GS-elav) flies compared with w;UAS-Ab42;1 (UAS-Ab42/1) and w;1;GS-elav-GAL4 (GS-elav/1) control flies treated (1) or untreated (-) with RU486 for 3 days assessed by RT-qPCR. B: Induction of dFabp mRNA in Ab42; GS-elav flies compared with UAS-Ab42/1 and GS-elav/1 control flies treated (1) or untreated (-) with RU486 for 3 or 4 days assessed by RT-qPCR. Values are mean 6 SEM; n 5 50 per replicate, six replicates/genotype. ***P < 0.001, two-tailed Student's t-test, equal variance.
indicate that constitutive neuronal Ab expression may regulate diurnal dFabp protein levels but does not affect dFabp mRNA levels.
Ab-Induced Sleep Loss Is Rescued by Fabps
Previously, we have shown that overexpression of either dFabp or mouse brain Fabp (mFabp7) in Drosophila is able to modulate sleep and enhance cognitive performance (Gerstner et al., 2011a,b) . Therefore, we next examined whether the Ab42-induced sleep disruption in 2-or 3-day-old flies could be rescued by an extra copy of Fabp. We observed that the reduced sleep in Ab42/1 flies could be rescued in age-matched w,elav-GAL4;UASAb42;hs-dFabp(Ab42/1;dFabp/1) flies over the course of the day (P < 0.001, two-way ANOVA, factors genotype and time, post hoc Holm-Sidak; Fig. 4A ). We then determined the amount of total sleep (24 hr) in Ab42/1 flies and found a significant reduction in sleep compared with elav/Y and elav-GAL4;1;hs-dFabp(dFabp/1) controls, which was rescued by dFabp (P < 0.001, one-way ANOVA, post hoc Holm-Sidak; Fig. 4B ). Similar effects were observed for total sleep during day (Fig. 4C) and night (Fig. 4G ). This dFabp rescue of Ab-induced sleep loss was accompanied by an increase in daytime maximal bout length (Fig. 4E) , with nominal effects on other sleep 
A-F:
Comparison of daytime sleep profile in w;UAS-Ab42;GS-elav-GAL4 (Ab42;GS-elav) flies treated (1) or untreated (-) with RU486 averaged across 3 days assessed as minutes of sleep (A-C), number of bouts (D), consolidation (E) during the 12-hr light period, and consolidation (F) during the 12-hr dark period. G,H: Comparison of activity profile in Ab42;GS-elav flies treated (1) or untreated (-) with RU486 averaged across 3 days assessed as pixels moved during the light period (G) or the dark period (H). Values are mean 6 SEM; n 5 14 per group. *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed Student's t-test, equal variance (A-G). measures (Fig. 4D,F,H-J) . Control w;UAS-Ab42;hs-dFabp(UAS-Ab42/1;dFabp/1) flies (without the elav-GAL4 driver) had less total sleep time (24 hr) compared with UAS-Ab42/1 control flies, with nominal effects on other sleep measures (Fig. 5) . Control UAS-Ab42/1 and UASAb42/1;dFabp/1 flies did not exhibit any differences in sleep consolidation compared with the w(isoCJ1) isogenic background strain (Fig. 5F ). Previously, we have shown that heat-shock induction of dFabp in flies further augments sleep and enhances cognitive performance (Gerstner et al., 2011b) . Ab-induced sleep loss that was observed in Ab42/1 flies was rescued in Ab42/ 1;dFabp/1 flies with heat-shock treatment (P < 0.001, two-way ANOVA, factors genotype and time, post hoc Holm-Sidak; Fig. 8 ). These data suggest that Ab42-induced sleep loss can be rescued by Fabp.
Ab42-Induced Sleep Fragmentation Is Rescued by Fabps
Ab induces reductions in total sleep (Fig. 4B ) and maximal sleep-bout length (Fig. 4E) , and this suggests that constitutive neuronal Ab expression disrupts consolidated sleep. Therefore, we examined aspects of sleep fragmentation in Ab42/1 flies. Examples of individual diurnal sleep-bout histograms for each genotype showed Comparison of daytime profile in w;UAS-Ab42;GSelav-GAL4 (Ab42;GS-elav) flies treated (1) or untreated (-) with RU486 assessed as minutes of sleep (A,B) and pixels moved (C) during the 12-hr light period across 3 days (d1, d2, d3). D: Comparison of activity profile in Ab42;GS-elav flies treated (1) or untreated (-) with RU486 assessed as pixels moved during the night period across 3 days. Values are mean 6 SEM; n 5 14 per group (P < 0.001, twoway ANOVA, factors day and RU486 treatment, post-hoc HolmSidak). *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 4. Constitutive neuronal Ab42 disrupts sleep and is rescued by Fabp overexpression. A,B:
Comparison of diurnal sleep profile in 2-or 3-day-old w,elav-GAL4;UAS-Ab42;1 (Ab42/1) flies vs. control w,elav-GAL4;1;1 (elav/Y) flies, w,elav-GAL4;1;hs-dFabp (dFabp/1) flies, and w,elav-GAL4;UAS-Ab42;hs-dFabp (Ab42/1;dFabp/1) flies assessed as minutes of sleep during the full 24-hr period. Significance for each point is shown below the x-axis in A. C-F: Comparison of daytime sleep profile in 2-or 3-day-old Ab42/1 flies vs. control elav/Y, w, dFabp/1 and Ab42/1; dFabp/1 flies assessed as minutes of sleep (C-E) and number of bouts (F) during the 12-hr light period. G-J: Comparison of nighttime sleep profile in 2-or 3-day-old Ab42/ 1 flies vs. control elav/Y, w, dFabp/1 and Ab42/1; dFabp/1 flies assessed as minutes of sleep (G-I) and number of bouts (J) during the 12-hr dark period (elav/Y and Ab42/1 n 5 40/group; dFabp/1 n 5 36; Ab42/1; dFabp/1 n 5 34). Values are mean 6 SEM (P < 0.001 two-way ANOVA, factors genotype and time, post hoc HolmSidak [A]; P < 0.001 one-way ANOVA, post hoc Holm-Sidak [B-J]). *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant. that timing and length of sleep bouts were altered in Ab42/1 flies compared with controls and that the Ab42-induced sleep fragmentation was rescued in Ab42/ 1;dFabp/1 flies (Fig. 9A-D) . We also measured nighttime sleep consolidation and observed that Ab42/1 flies had a reduced CI compared with controls, which was rescued in Ab42/1;dFabp/1 flies (Fig. 9E) .
To determine whether these Ab42-induced effects can be rescued by the mammalian ortholog, we also examined sleep in Ab42/1 flies carrying a copy of the Fig. 5 . Control w;UAS-Ab42;1 and w;UAS-Ab42;hs-dFabp flies do not exhibit any difference in sleep consolidation compared with w (isoCJ1) isogenic background strain. A-F: Comparison of sleep profile in 2-or 3-day-old isogenic background strain control w (isoCJ1) flies vs. control w;UAS-Ab42;1 (UAS-Ab42/1) and w;UAS-Ab42;hsdFabp (UAS-Ab42/1;dFabp/1) flies assessed as minutes of sleep for the 24-hr period (A), and as minutes of sleep (B-D), number of bouts (E), and CI (F) during the 12-hr dark period. Values are mean 6 SEM (w[isoCJ1] n 5 74/group; UAS-Ab42/1 n 5 74; UAS-Ab42/ 1; dFabp/1 n 5 49). *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA, post hoc Holm-Sidak.
mouse Fabp mFabp7. As with Ab42/1;dFabp/1 flies, we observed an increase in nighttime sleep in w,elav-GAL4;UAS-Ab42;hs-mFabp7(Ab42/1;mFabp7/1) flies (Fig. 10A ). This increase in sleep was also accompanied by an increase in average night sleep-bout length (Fig.  10B ) and average nighttime maximal bout length (Fig.  10C) . No change was observed in night bout count (Fig.  10D) . The sleep CI was also augmented in Ab42/ 1;mFabp7/1 flies (Fig. 10E) . Expression of mFabp7 mRNA was only observed in Ab42/1;mFabp7/1 overexpressing flies and was not detected in elav/Y,UASAb42/1, or Ab42/1;dFabp/1 flies (Fig. 6B) . Altogether, these data indicate that Ab42 induces sleep fragmentation and that expressing either fly or mammalian Fabp7 is sufficient to rescue this effect.
Constitutive Neuronal Expression of Human Ab Increases Activity
Because we had previously demonstrated that constitutive neuronal Ab expression induces fragmented sleep, we also tested whether the presence of Ab is associated with changes in locomotor activity. Therefore, we examined movement in Ab42/1 flies and found that there was an increase in pixels moved compared with controls (Fig. 11A,B) , which was more pronounced at night (Fig. 11C,D) . Rescue of Ab-induced activity was observed in Ab42/1;dFabp/1 flies (P < 0.001, two-way ANOVA, factors genotype and time, post hoc HolmSidak; Fig. 11A,B) . Movement per minute of wakefulness, a measure used to indicate differences in hyperactivity, differs from normal activity measures (pixels moved) because it accounts for the amount of activity per unit time spent awake. Hyperactivity did not differ in Ab42/ 1 flies compared with controls during the day or the night ( Fig. 11E,F) , suggesting that the mechanism for Ab-induced activity is at least partially distinct from that for Ab-induced sleep disturbance associated with hyperactivity.
DISCUSSION
This study indicates that human Ab disrupts sleep in a Drosophila model of AD. Inducible transgenic neuronal expression of Ab disrupted daytime consolidated sleep. These data provide evidence suggesting that neuronal Ab expression alone is able to disrupt sustained periods of sleep prior to long-term accumulation and subsequent aggregation. Constitutive neuronal Ab expression disrupted consolidated nighttime sleep and reduced total sleep time in flies 2 or 3 days posteclosion (or 2-or 3-day-old flies). We were able to rescue this Ab-induced sleep fragmentation in transgenic flies carrying an additional copy of dFabp. Similar findings were observed in transgenic flies carrying a copy of the mouse brain-type Fabp mFabp7. These findings indicate that Ab alone can perturb consolidated sleep behavior and that Fabp genes rescue Ab-induced sleep fragmentation.
The sleep/wake cycle is a behavior that occurs broadly throughout animal phyla and is an essential property of normal brain function. Disturbances in sleep across many species, including flies, mice, and humans, have been shown to cause cognitive impairment and memory deficits (Graves et al., 2001; McDermott et al., 2003; Ganguly-Fitzgerald et al., 2006; Abel et al., 2013; Goel et al., 2013) . Ab accumulation is also believed to cause cognitive deficits across these species (Iijima et al., 2004; Lesne et al., 2006 Lesne et al., , 2013 Kittelberger et al., 2012) . It has Fig. 6 . Expression of dFabp mRNA is normal in w,elav-GAL4;UASAb42;1 flies. A: qPCR results of dFabp mRNA in 2-or 3-day-old w,elav-GAL4;UAS-Ab42;1 (Ab42/1) fly heads compared with w,elav-GAL4;1;1 (elav/Y) and w;UAS-Ab42;1 (UAS-Ab42/1) control flies. Also shown are w,elav-GAL4;UAS-Ab42;hs-dFabp (Ab42/1;dFabp/1) and w,elav-GAL4;UAS-Ab42;hs-mFabp7 (Ab42/ 1;mFabp7/1) flies. No significant differences were observed between groups (one-way ANOVA, n 5 6/group, each group consisted of 50 heads). B: RT-qPCR results of mFabp7 mRNA in the heads of 2-or 3-day-old Ab42/1; mFabp7/1 flies compared with elav/Y, UAS-Ab42/1, Ab42/1, and Ab42/1; dFabp/1 flies. Values represent means 6 SEM; n 5 6/group, each group consisted of 50 heads. Significant differences were observed between groups. ***P < 0.001, one-way ANOVA, Holm-Sidak post hoc.
been shown that circadian rhythms are affected by neural expression of Ab in flies while the molecular clock remains intact (Chen et al., 2014) , suggesting that Ab may influence other behaviors, such as sleep. A recent study indicated that increases in Ab led to reduced and fragmented sleep in Drosophila (Tabuchi et al., 2015) , similarly to our observations here. Studies on AD mouse models and AD patients also support a role for Abassociated sleep/wake perturbations (Vitiello and Borson, 2001; Wisor et al., 2005; Zhang et al., 2005; Wu and Swaab, 2007; Jyoti et al., 2010) . Whether Ab affects consolidated sleep at ages prior to the onset of amyloidassociated cognitive decline has remained elusive; however, sleep disturbance may be a preclinical marker of AD, occurring at ages before cognitive disturbance (Ju et al., 2014; Lim et al., 2014 ). Here we found that shortterm expression of Ab disrupted consolidated sleep in flies, although these effects were specific to daytime. Short-term Ab expression reduced daytime sleep consolidation (Fig. 2E ) but tended to increase nighttime sleep consolidation (Fig. 2F) . This induced expression occurred on a time scale within days (Fig. 1) ; therefore, the differences in daytime and nighttime sleep consolidation likely are from short-term effects of Ab rather than from longterm effects that may include more extracellular accumulation. We also provide evidence that long-term expression of Ab is able to disrupt daytime and nighttime sleep (Fig. 4) . Flies with constitutive neuronal Ab expression exhibit loss of both daytime and nighttime sleep at an age that precedes learning deficits previously reported with this same model (Iijima et al., 2004 ). Short-term expression of Ab already disrupts sleep (albeit daytime sleep; Figs. (2 and 3) ), whereas long-term Ab expression disrupts both daytime and nighttime sleep that is rescued by dFabp and mFabp7 (Figs. (4 and 9) , 10), suggesting that chronic Ab expression generates progressive sleep loss and that this progressive sleep loss can be rescued by Fabp. This also suggests that disrupted sleep may be prodromal to Ab-associated cognitive decline in AD. It has been shown that interstitial levels of Ab increase in the brains of young AD model mice during wakefulness and decrease during sleep (Roh et al., 2012) even in the absence of Ab plaques, similarly to wakefulness-associated levels of Ab in human CSF fluid (Bateman et al., 2007; Huang et al., 2012) . Our results show that short-term Ab expression results in decreased sleep in flies, indicating that the Ab peptide can induce wakefulness, albeit only in the daytime. On the other hand, our results demonstrate that long-term constitutive neuronal expression of Ab is capable of disrupting both daytime and nighttime sleep, suggesting that Ab aggregation may be responsible for perturbing consolidated nighttime sleep, similarly to recent reports (Tabuchi et al., 2015) . Our study did not discriminate between intracellular and extracellular Ab accumulation over time; however, other studies using similar models have indicated a relationship between Ab accumulation and sleep disruption (Ju et al., 2014; Lim et al., 2014) . It has been shown that Ab aggregation leads to dysregulation of the sleep/wake cycle and that sleep deprivation in turn produces further Ab aggregation (Roh et al., 2012; Tabuchi et al., 2015) . Recently, sleep has been shown to facilitate clearance of Ab in mammals (Xie et al., 2013) and to reduce Ab accumulation in flies (Tabuchi et al., 2015) . Levels of Ab in human CSF associated with deposition were also linked to sleep disruption in preclinical AD (Ju et al., 2013) . Altogether, these data suggest a positive feedback loop among sleep/wake behavior and Ab levels, metabolism, and aggregation (Gerstner et al., 2012a; Lim et al., 2014 ). An early disruption in consolidated sleep may accelerate Ab accumulation, which would lead to further wakefulness-associated Ab release, aggregation, sleep disruption, and cognitive loss (Kang et al., 2009; Gerstner et al., 2012a) . Future longitudinal studies in animal models and humans are required to assess whether such a relationship between AD pathology and disruption in sleep/wake states exists.
Previously, we and others have shown changes in the time-of-day expression of dFabp mRNA in normal flies (Ceriani et al., 2002; Gerstner et al., 2011b) and Fabp7 mRNA in mice (Panda et al., 2002; Gerstner et al., 2006 Gerstner et al., , 2008 Gerstner et al., , 2012b . Additionally, we have shown that flies that overexpress dFabp or mFabp7 have improved cognitive performance and increased sleep (Gerstner et al., 2011b) . We have also reported that the relative nuclear to cytoplasmic ratio of Fabp correlates with specific forms of cognitive performance in flies (Gerstner et al., 2011a) . Recently it has been shown that increasing dFabp expression rescues memory deficits in learning and memory in mutant flies and that sleep reverses memory defects in a fly Alzheimer's model (Dissel et al., 2015) . Our studies suggest that the Ab-induced nighttime sleep fragmentation can be rescued genetically with additional copies of either dFabp or mFabp7. It remains possible that increasing Fabp expression may enhance sleep through compensatory mechanisms rather than restoring sleep because it mitigates the impact of Ab on sleep. Future studies determining functional relationships between Fabp expression and Ab aggregation will be important for understanding the relationships among Ab, Fabp, and sleep. Although we used the mFabp7 transgenic flies because of our previous studies (Gerstner et al., 2011a,b) , future work using hFabp7 transgenic flies will be important for determining whether the human Fabp7 ortholog can ameliorate the negative effects of Ab on sleep. Additional studies focused on determining whether reducing Fabp expression leads to sleep loss and negatively affects Ab aggregation will also be important to elucidate mechanisms relating Ab, Fabp, and sleep. Because we cannot rule out possible developmental effects in our model, Fragmented sleep in Ab42/1 flies is indicated by arrows. E: CI during the ZT12-24-hr dark period in 2-or 3-day-old w,elav-GAL4;UAS-Ab42;1 (Ab42/1) flies vs. w,elav-GAL4;1;1 (elav/Y) flies, w,elav-GAL4;1;hs-dFabp (dFabp/1) flies, and w,elav-GAL4;UAS-Ab42;hs-dFabp (Ab42/1;dFabp/1) flies (elav/Y n 5 31; Ab42/1 n 5 32; dFabp/1 n 5 37; Ab42/1; dFabp/ 1 n 5 26). Values are mean 6 SEM (P < 0.001 one-way ANOVA, post hoc Holm-Sidak). **P < 0.01, ***P < 0.001. Open bars, light period; solid bars, dark period. future studies seeking to determine whether Fabp can also rescue cognitive deficits, Ab42 aggregation, and reduced longevity in the inducible Ab42;GS-elav fly model will be important for understanding Fabp pathways in AD. Previous studies have shown progressive learning impairments that first appear in males (but not females) by 6-7 days old, with further learning deficits in both genders by 14-15 days of age (Iijima et al., 2004) . Future studies examining whether female flies have a similar delay in the progression of sleep deficits compared with males and whether gender differences in Fabp expression exist will be important for determining how generalizable the effects of Fabp expression are on Ab-associated sleep disruption. It is also important to note that the model used in our study does not address other aspects of AD pathogenesis, such as tau pathology. For example, tau may influence sleep in ways that are independent of Ab (Di Meco et al., 2014; Menkes-Caspi et al., 2015) . Therefore, although our data suggest a pathway involved in Abderived sleep fragmentation, they may not fully capture the complex relationship between sleep and AD pathology.
Abnormal Fabp levels in CSF and blood plasma have recently been shown to be associated with AD (Chiasserini et al., 2010; Ohrfelt et al., 2011; Teunissen et al., 2011; Desikan et al., 2013; Guo et al., 2013; O'Bryant et al., 2013; Olsson et al., 2013; ) . Although levels of Fabp in the CSF were shown to be elevated in AD patients compared with cognitively normal subjects (Hu et al., 2010) , levels of Fabp3 within the brains of AD patients were actually lower (Cheon et al., 2003) , in agreement with our results in Drosophila. These data suggest an inverse relationship in relative Fabp levels between brain tissue and CSF in AD, in opposition to that observed for Ab levels in AD. Studies in human AD support an inverse correlation between brain and CSF amyloid load (Fagan et al., 2006; Forsberg et al., 2008; Grimmer et al., 2009) . Alterations in normal Fabp levels observed in AD may contribute to AD-associated sleep disturbances. Although the precise mechanisms responsible for Ab42-induced sleep disruption are not known, our results show that having an extra copy of Fabp can ameliorate these sleep deficits. Fabp7 binds the omega-3 fatty acid DHA with high affinity (Xu et al., 1996) , and DHA-mediated nuclear localization of Fabp7 is thought to regulate PPAR transactivity (Mita et al., 2010) . Given that polyunsaturated fatty acids such as DHA can rescue cognitive decline in AD animal models and have been suggested to reduce the risk of AD in humans (Calon and Cole, 2007; Boudrault et al., 2009) , DHA may be operating through Fabp7 nuclear translocation and targeting of PPAR-mediated transcription. PPAR activation has been shown to facilitate the clearance of Ab in AD animal models (Mandrekar-Colucci et al., 2012; Yamanaka et al., 2012) , and, because DHA triggers nuclear localization of Fabp7 to regulate PPAR-mediate transcription (Mita et al., 2010) , this pathway may represent one mechanism relating Fabp7 with reducing Ab accumulation and consolidated sleep. DHA is also thought to reduce oxidative stress and inflammation, both of which are associated with AD (Dyall, 2010) . One way in which Ab may contribute to neurodegeneration in AD is by inducing oxidative stress through lipid peroxidation in brain cell membranes and increased production of 4-hydroxynonenal (Butterfield and Lauderback, 2002) . Fabps have been shown to be modified by 4-hydroxynonenal (Bennaars-Eiden et al., 2002; Hellberg et al., 2010) and, therefore, may represent Comparison of night sleep profile in w,elav-GAL4;UAS-Ab42;1 (Ab42/1) flies vs. w,elav-GAL4;UASAb42;hs-mFabp7 (Ab42/1;mFabp7/1) flies assessed as minutes of sleep (A-C) and number of bouts (D) during the 12-hr dark period. E: CI during the 12-hr dark period (Ab42/1 n 5 31; Ab42/1; mFabp7/1 n 5 25). Values are mean 6 SEM. *P < 0.05, **P < 0.01, two-tailed Student's t-test, equal variance.
one scavenging mechanism to operate as an antioxidant protein in response to lipid peroxidation generated by Ab. Fabp overexpression in flies has been shown to increase longevity and resistance to oxidative stress (Lee et al., 2012) , supporting a role for this concept in the normal aging process. Future work determining whether Fabp expression influences Ab42 clearance mechanisms or oxidative load and whether Ab42 affects Fabp levels or nuclear localization across sleep/wake states will be important for evaluating mechanisms associated with sleep disturbance in AD.
Sleep amount and quality are known to decline with age. This effect is even more pronounced in AD and is a major contributing factor for institutionalization. Here, we show that sleep quality is significantly disrupted in a Drosophila AD model at an age that precedes other previously established phenotypic markers. Furthermore, we can rescue the sleep fragmentation genetically with Fabp overexpression. These studies implicate Fabp signaling pathways in mediating Ab-induced sleep/wake fragmentation and provide further support for Drosophila as a model organism with which to study the relationships among Ab, sleep/wake behavior, and AD.
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